Colorectal Cancer

Study: Expanded access to Medicaid coverage under the Affordable Care Act is linked to reduced cancer mortality

In 2014 the Affordable Care Act expanded Medicaid coverage. How did this affect healthcare for cancer patients? This study shows that deaths from breast, colorectal and lung cancer are lower in states that chose to expand Medicaid compared to states that did not. Early diagnosis was linked to lower death rates. This suggests that increased healthcare access may lead to earlier cancer detection and better outcomes, including lower mortality. (3/31/2021)

Este artículo está disponible en español.

Study: Body Mass Index (BMI) may affect how well aspirin use protects against colorectal and ovarian cancer

This study looked at the impact of daily aspirin use on the risk for many types of cancers and whether this effect can be modified by risk factors such as obesity, smoking, physical inactivity or a family history of cancer. Daily aspirin use: 

• lowered the risk for colorectal cancer, but this effect was lost as Body Mass Index (BMI) increased.
• lowered the risk of ovarian cancer risk among obese women.
• offered little or no protection against breast, endometrial or advanced prostate cancer.

(posted 3/19/21)

Este artículo está disponible en español.

Study: Immunotherapy drug Keytruda received FDA approval and showed benefit for treatment of colorectal cancer

In June 2020, the FDA approved Keytruda (pembrolizumab) as an initial therapy for advanced colorectal cancer. This approval was based on the results from the KEYNOTE-177 study. In this study, Keytruda was more successful than chemotherapy in delaying progression of certain types of colorectal cancers. (11/25/20)

Study: Cancer risk associated with inherited mutations in Lynch syndrome genes

Lynch syndrome is the most common inherited cause of cancer affecting about 1 in 300 people. People with Lynch syndrome have an increased risk of colorectal endometrial and other cancers. A large study followed people with mutations in the Lynch syndrome genes MLH1, MSH2, MSH6 and PMS2 to determine the risk of other types of cancer. (2/21/20)

Study: LGBTQ patients recommend improvements for their cancer care

Very little research has focused on the cancer care experiences of lesbian, gay, bisexual, transgender and queer (LGBTQ) people. This study looks at recommendations from the LGBTQ community for improving their cancer care. (6/20/19)

Article: The importance of racial diversity in clinical trials

This article by journalists Caroline Chen and Riley Wong looks at racial disparities between participation in clinical trials and the population of people with cancer. (11/6/18)

Este artículo está disponible en español.

Study: Evaluation of some direct-to-consumer genetic testing reveals inaccuracies and misinterpretations

A clinical genetic testing laboratory examined results from direct-to-consumer genetic testing ordered directly by patients. They found many instances of false positives—reported mutations that were not actually present—and in some cases, reports of variants that "increased risk," but were actually benign. This study emphasized the importance of involving genetics experts in the interpretation of genetic test results. (6/28/18)

Study: Mutations in Lynch syndrome genes MSH6 and PMS2 may be associated with breast cancer

Some women with mutations in MSH6 and PMS2, two Lynch syndrome genes, may have a modest (2 to 3-fold) increased risk for breast cancer. (6/14/18 updated 09/25/19)

Study: Cancer “vaccine” injected directly into tumors works in mice

Immunotherapy is treatment that uses the immune system to fight cancer. Still in its infancy, it is a promising therapy that is changing how certain cancers are treated. A new study reports that tumors in lab mice were eliminated when they were injected with two immune system-enhancing agents. This new approach is called in situ (at the original site) vaccination because the injections are given directly into the tumors. It worked on several different types of mouse tumors, including lymphomas and breast tumors. This approach may be safer than conventional immunotherapy because it uses very low doses of the agents and it does not require tumors to have particular markers. (02/23/18)

Study: Genetic counseling by phone or face-to-face

Results presented at the 2017 American Psychological Association’s annual meeting showed genetic counseling by telephone is as “safe and effective” in long-term psychological and social outcomes compared to traditional in-person counseling for women at risk for hereditary breast and ovarian cancer. This presentation is an update on research published in 2014. (11/29/17)